摘要
随着乳腺癌早期诊断率的逐步提高,对激素受体阳性、淋巴结阴性的乳腺癌患者,运用21基因复发风险评分来决策治疗,已逐步被临床医师所接受,但其在激素受体阳性、淋巴结阳性的早期乳腺癌治疗中的地位仍在不断地探讨中。本文将通过对几个临床研究结果的分析,来阐述激素受体阳性、腋窝淋巴结阳性的早期乳腺癌复发评分结果对治疗决策的意义。
With the recently increasing number of the women newly diagnosed with early breast cancer（EBC）, the 21-gene recurrence score assay has been clinically validated and recommended for the treatment decisionmaking in patients with ER（＋）, node-negative（N0） EBC. A growing body of evidence from several large phase Ⅲ clinical trials reports similar findings in patients with ER（＋）, N（＋） EBC. This assay could help guide treatment decisions for the patients who are most likely to receive benefit from chemotherapy.
出处
《肿瘤防治研究》
CAS
CSCD
北大核心
2016年第6期534-537,共4页
Cancer Research on Prevention and Treatment
